

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊




QK1818309

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6

中国新药杂志



7

2018

Vol.27 | No.7

酪氨酸激酶抑制剂在我国专利布局研究
啮齿类动物多器官微核试验的最新进展
注射用丹参多酚酸对阿司匹林在大鼠体内的药动学与药效学影响
HIV蛋白酶抑制剂硫酸阿扎那韦的原料药合成研究进展
瑞巴派特治疗幽门螺杆菌阳性胃溃疡90例的疗效及细胞因子变化

www.newdrug.cn

ISSN 1003-3734



9 771003 3734 07

万方数据

国家食品药品监督管理总局主管



目次

半月刊 1992年创刊

第27卷第7期 2018年4月15日出版

•新药述评与论坛•

- 729 酪氨酸激酶抑制剂在我国专利布局研究.....武莹, 顾东蕾, 戴静雪
738 仿制药生物等效性试验中基于PDCA模式的血样质量管理.....曹端文, 陈英, 左荣, 等
742 小分子抗癌药物埃克替尼专利技术分析.....原静

•新药注册与审评技术•

- 747 关于药物制备工艺中“过量投料”现象的分析与评价思路.....张星一, 田娜

•重大新药创制专项巡礼•

- 751 啮齿类动物多器官微核试验的最新进展.....童文, 周长慧, 常艳
756 缩宫素中升压物质检查探讨.....张媛, 李震, 吴彦霖, 等
761 注射用丹参多酚酸对阿司匹林在大鼠体内的药动学与药效学影响.....张文静, 褚扬, 刘万卉, 等

•综述•

- 767 HIV蛋白酶抑制剂硫酸阿扎那韦的原料药合成研究进展.....白跃飞, 刘举, 周宏, 等
781 津力达颗粒治疗2型糖尿病的研究进展.....张慧, 刘红利, 张玉福, 等
786 非酒精性脂肪性肝炎治疗药物临床研究进展.....陈颖, 鲁爽, 王涛
791 纳米载体-温敏凝胶复合体系递送抗癌药物的研究进展.....苏平, 曲柯润, 蒋金金, 等
797 铁-糖复合物注射剂相似性评价研究进展.....金雪峰, 刘留成, 宗在伟, 等

•临床研究•

- 803 维格列汀片空腹人体生物等效性研究.....江思艳, 童九翠, 胡骅, 等
807 替格瑞洛对择期冠脉支架植入术患者造影剂肾病发病率影响.....张倩, 刘晓刚, 白玉鹏, 等
812 瑞巴派特治疗幽门螺杆菌阳性胃溃疡90例的疗效及细胞因子变化.....刘新尧, 王晓辉, 闫志辉, 等

•实验研究•

- 817 SPG复方对CCl₄致小鼠急性肝损伤的保护作用.....杨春梅, 胡源霖, 侯俊玲, 等
822 赛乐西帕的合成工艺.....方倩, 王辉, 尚振华
827 法舒地尔3种有机杂质的合成.....彭嘉勋, 刘凯清, 毛雨
830 复方莪术油脂体凝胶的制备及体外透皮作用.....陈积, 赵小倩, 马彦巧, 等
839 中药复方制剂益艾康胶囊HPLC指纹图谱研究.....孟菲, 桂新景, 秦会珍, 等
843 HPLC法测定注射用甲磺酸普依司他的含量.....陈英杰, 朱伊婷, 夏媛媛, 等

[期刊基本参数] CN11-2850/R*1992*sm*A4*120*zh*P*¥30.00**21*2018-04

责任编辑 王韧 英文审校 魏尔清 杜小莉 张鲸惊

万方数据

- 729 Patent layout of tyrosine kinase inhibitor in China
WU Ying, GU Dong-lei, DAI Jing-xue
- 738 PDCA for blood & plasma samples quality management in bioequivalence study
CAO Duan-wen, CHEN Ying, ZUO Rong, *et al*
- 742 Patent technology analysis for icotinib—a kind of small molecule antitumor drug
YUAN Jing
- 747 Analysis and evaluation of excessive feeding in the R&D and manufacture procedure of medicines
ZHANG Xing-yi, TIAN Na
- 751 Micronucleus assays in rodent tissues other than bone marrow
TONG Wen, ZHOU Chang-hui, CHANG Yan
- 756 Study on the vasopressor activity test of oxytocin
ZHANG Yuan, LI Zhen, WU Yan-lin, *et al*
- 761 Effect of Salvianolic acid for injection on pharmacokinetics and pharmacodynamics of aspirin in rats
ZHANG Wen-jing, CHU Yang, LIU Wan-hui, *et al*
- 767 Research progress on the synthesis of HIV protease inhibitors atazanavir sulfate
BAI Yue-fei, LIU Ju, ZHOU Hong, *et al*
- 781 Research progress of Jinlida granule in the treatment of type 2 diabetes mellitus
ZHANG Hui, LIU Hong-li, ZHANG Yu-fu, *et al*
- 786 Advances in clinical development of pharmacotherapy for nonalcoholic steatohepatitis
CHEN Ying, LU Shuang, WANG Tao
- 791 Progress in research of nanocarrier-thermogels as composite drug delivery system for anticancer drug
SU Ping, QU Ke-run, JIANG Jin-jin, *et al*
- 797 Similarity evaluation of intravenous iron carbohydrate complexes
JIN Xue-feng, LIU Liu-cheng, ZONG Zai-wei, *et al*
- 803 Bioequivalence of vildagliptin tablets in healthy volunteers
JIANG Si-yan, TONG Jiu-cui, HU Hua, *et al*
- 807 Effect of ticagrelor on incidence of contrast induced nephropathy in patients undergoing elective coronary stent implantation
ZHANG Qian, LIU Xiao-gang, BAI Yu-peng, *et al*
- 812 The effect and change of the cytokines of 90 *Helicobacter pylori* positive gastric ulcer cases in the treatment of rebamipide
LIU Xin-yao, WANG Xiao-hui, YAN Zhi-hui, *et al*
- 817 Protective effects of SPG preparation on the acute liver injury induced by CCl₄ in mice
YANG Chun-mei, HU Yuan-lin, HOU Jun-ling, *et al*
- 822 Synthetic process of selexipag
FANG Qian, WANG Hui, SHANG Zhen-hua
- 827 Synthesis of three organic impurities of fasudil
PENG Jia-xun, LIU Kai-qing, MAO Yu
- 830 Preparation and *in vitro* transdermal permeation of zedoary turmeric oil compound liposomes gel
CHEN Ji, ZHAO Xiao-qian, MA Yan-qiao, *et al*
- 839 Study on HPLC fingerprint of Yi'aikang capsule
MENG Fei, GUI Xin-jing, QIN Hui-zhen, *et al*
- 843 HPLC determination of purinostat mesylate for injection
CHEN Ying-jie, ZHU Yi-ting, XIA Yuan-yuan, *et al*

Directed by: China Food and Drug Administration
Sponsored by: China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association
Editor-in-Chief: SANG Guo-wei
Board Chairman: SHI Sheng-yi
Edited by: Editorial Board of Chinese Journal of New Drugs
Published by: Chinese Journal of New Drugs Co., Ltd.
Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China
Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>
E-mail: bianjibu@newdrug.cn
Printer: Beijing Kexin Printing Co., Ltd.
Domestic Distribution: Beijing Post Offices
Overseas Distribution: China International Book Trading Corp.
(P.O.Box 399 Beijing, China)
Domestic Subscription: Local Post Offices
Periodical Registration: ISSN 1003-3734 CN 11-2850/R
Publication Date: April 15, 2018
Copyright: 2018 by Chinese Journal of New Drugs Co., Ltd.



晴众
富马酸替诺福韦二吡呋酯片
Tenofovir Disoproxil Fumarate Tablets

广告

臻睛真意 惠艾万众

慢性乙型肝炎抗病毒治疗一线药物
国内率先通过《仿制药质量和疗效一致性评价》
开展与原研替诺福韦酯五年期“头对头”临床试验



晴众®简要处方资料

- 【药品名称】商品名：晴众®
通用名：富马酸替诺福韦二吡呋酯片
- 【适应症】本品适用于治疗慢性乙型肝炎成人和≥12岁的儿童患者；与其他抗逆转录病毒药物联用，治疗成人HIV-1感染。
- 【规格】300mg
- 【用法用量】成人和12岁及以上儿童患者（35kg或以上）口服本品，每日1次，每次300mg，可空腹或与食物同服。
- 【不良反应】临床试验中最常见的不良反应包括消化道事件、头痛、头晕、乏力、鼻咽炎、疼痛、皮疹、抑郁、失眠、淀粉酶增加、肝酶升高和肌酐升高等。
- 【禁忌】富马酸替诺福韦二吡呋酯片禁用于先前对本药物中任何一种成份过敏的患者。



(详细资料备索)

苏药广审(文)：第2017120671号

@ HTTP://WWW.CTTQ.COM

健康咨询热线：800 828 5598

本广告仅供医学、药学专业人士阅读

万方数据

国内定价：30.00元 国内统一刊号CN11-2850/R 邮发代号82-488 国外代号M4240

正大天晴药业集团
CHIA TAI TIANG PHARMACEUTICAL GROUP